EBS
Emergent BioSolutionsDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
8
U.S. public peers
Grade Position
In line
vs peer average
EBS vs peer average
46/100
EBS vs. peer average (D vs. D)
Grade spread
B 2 · C 1 · D 2 · F 3
Graded peers loaded
Coverage
8 graded
100% of tracked
Peer overview
RLMD is the first available peer comparator.
Same sector: Pharmaceuticals, Biotechnology & Life Sciences · Cap $342.41M
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
EBS
Emergent BioSolutions
RLMD
Relmada Therapeutics
Grade
D
D
Momentum
69
8
Value
71
41
Sentiment
24
54
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Grade position vs RLMD
EBS / RLMD
Grade Position
In line
EBS vs. peer average (D vs. D)
46/100
Momentum
69
EBSValue
71
EBSSentiment
24
RLMDRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs EBS
RLMD is the first peer returned for this comparison set.